BG Medicine Announces Availability of Galectin-3 Diagnostic Testing Through Mayo Medical Laboratories
5/14/2012 9:46:09 AM
WALTHAM, Mass., May 14, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, announced today that Mayo Medical Laboratory (Mayo) now offers galectin-3 testing services to its laboratory customers and physicians. Mayo will offer the BGM Galectin-3TM test, which was cleared by the U.S. Food and Drug Administration in November 2010, as an aid in assessing the prognosis of patients diagnosed with chronic heart failure. Galectin-3 testing provides physicians with clinical information on fibrosis formation and cardiac remodeling, which are important biological processes in the development and progression of heart failure. BG Medicine plans to continue to expand commercial availability of its BGM Galectin-3 test through major U.S. laboratories.
comments powered by